Search Results 181-190 of 7931 for TNF

  1. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Mayo Clinic

    ... TNF agents, and rituximab). Subjects with an MMT-8 score ≤ 66 (see Appendix ... tumor necrosis factor receptor associated periodic syndrome. Read More ...

  2. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to cycle 1 day 1: Patients who have received acute, low dose, systemic immunosuppressant ...

  3. Publications - Zeying Du, M.D., Ph.D. - Mayo Clinic

    1999; 30(3):242-245. View PubMed; Du ZY, Li XY. Effects of ginkgolides on interleukin-1, tumor necrosis factor-alpha and nitric oxide production by rat ...

  4. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

    ... TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study. Note ...

  5. A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis - Mayo Clinic

    ... TNF, anti-IL-5, anti-IL-5 receptor, dupilumab, anti-IgE antibodies, omalizumab) or systemic corticosteroids with a daily dose >10 mg of prednisone or ...

  6. A Study to Assess the Effectiveness and Safety of Apremilast in Pediatric Patients (6 through 17 years old) with Moderate-to-Severe Plaque Psoriasis - Mayo Clinic

    Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to ...

  7. Early Fluconazole Treatment for Coccidiodomycosis Pneumonia - Mayo Clinic

    ... TNF medications, or other parenterally-administered immunomodulating agents; History of a solid organ or bone marrow transplant. Have poorly controlled HIV ...

  8. RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel for Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    ... TNF agents) within 2 weeks prior to initiation of study treatment: Participants who have received acute, low-dose, systemic immunosuppressant medications ...

  9. FrαDcs or Placebo for Patients With Advanced Stage Ovarian Cancer - Mayo Clinic

    ... tumor necrosis factor (TNF)-α agents) ≤ 2 weeks prior to registration, or anticipation of need for systemic immunosuppressive medication during the course ...

  10. Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1: Patients who have received acute, low dose, systemic immunosuppressant ...